BMY Q2 2018 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$121B

Q2 2018 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$5.7B+10.9% YoY

Gross Profit

$4.1B72.0% margin

Operating Income

$559M9.8% margin

Net Income

$373M6.5% margin

EPS (Diluted)

$0.23

QoQ Revenue Growth

+9.8%

Cash Flow

Operating Cash Flow

$1.1B

Free Cash Flow

$859M

Stock-Based Comp.

$51M

Balance Sheet

Total Assets

$32.6B

Total Liabilities

$20.2B

Stockholders' Equity

$12.3B

Cash & Equivalents

$5.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5.7B	$5.1B	+10.9%
Gross Profit	$4.1B	$3.8B	+9.3%
Operating Income	$559M	$1.5B	-62.8%
Net Income	$373M	$916M	-59.3%

Revenue Segments

Eliquis

$1.6B29%

Opdivo

$1.6B29%

Orencia

$711M12%

Sprycel

$535M9%

Other Legacy Brands

$421M7%

Yervoy

$315M6%

Baraclude

$179M3%

Reyataz

$117M2%

Sustiva Franchise

$73M1%

Empliciti

$64M1%

Hepatitis C Portfolio

$12M0%

Geographic Segments

UNITED STATES

$3.2B57%

Europe

$1.4B25%

Rest Of World

$923M16%

Other Region

$143M3%